共 50 条
JAK Inhibitors for Treatment of Alopecia Areata
被引:56
|作者:
Wang, Eddy H. C.
[1
]
Sallee, Brigitte N.
[1
]
Tejeda, Christina I.
[3
]
Christiano, Angela M.
[1
,2
]
机构:
[1] Columbia Univ, Dept Dermatol, 1150 St Nicholas Ave,Room 3038, New York, NY 10032 USA
[2] Columbia Univ, Genet & Dev, 1150 St Nicholas Ave,Room 3038, New York, NY 10032 USA
[3] Columbia Univ, Columbia Coll Phys & Surg, 1150 St Nicholas Ave,Room 3038, New York, NY 10032 USA
关键词:
COMORBIDITY PROFILES;
TOFACITINIB;
RUXOLITINIB;
PATIENT;
UNIVERSALIS;
REVERSAL;
VARIANTS;
VITILIGO;
ONSET;
D O I:
10.1016/j.jid.2018.05.027
中图分类号:
R75 [皮肤病学与性病学];
学科分类号:
100206 ;
摘要:
The advancement of genetic and preclinical studies has uncovered the mechanisms involved in the pathogenesis of alopecia areata (AA). The development of targeted therapies using small molecules blocking specific pathways for the treatment of AA is underway. By repurposing Food and Drug Administration-approved small molecule JAK inhibitors as treatments for AA, it has been demonstrated that JAK inhibitors can effectively reverse hair loss in patients with moderate to severe AA. In this review, we summarize and discuss the current preclinical and clinical studies on JAK inhibitors, as well as the prospects of using JAK inhibitors for the treatment of AA.
引用
收藏
页码:1911 / 1916
页数:6
相关论文